Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma

BACKGROUND: Cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, failed to show benefit over lomustine in relapsed glioblastoma. One resistance mechanism for cediranib is up-regulation of epidermal growth factor receptor (EGFR). This study aimed to det...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Nicholas, McBain, Catherine, Nash, Stephen, Hopkins, Kirsten, Sanghera, Paul, Saran, Frank, Phillips, Mark, Dungey, Fiona, Clifton-Hadley, Laura, Wanek, Katharina, Krell, Daniel, Jeffries, Sarah, Khan, Iftekhar, Smith, Paul, Mulholland, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883746/
https://www.ncbi.nlm.nih.gov/pubmed/27232884
http://dx.doi.org/10.1371/journal.pone.0156369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4883746/
https://www.ncbi.nlm.nih.gov/pubmed/27232884
http://dx.doi.org/10.1371/journal.pone.0156369

Ejemplares similares